Table 2.
Detailed overview of characterized antibodies
| Epitope | Antibody | Clonality | Company | Product N° | Concentration | Optimal dilution for IHC based on current study | Optimal concentration (μg/ml) for IHC based on current study |
|---|---|---|---|---|---|---|---|
| 3flag and flag | Anti-flag polyclonal1 | Polyclonal | Sigma | F7425 | 0.8 mg/ml | 1/5000 | 0.16 |
| FlagM21 | Monoclonal | Sigma | F3165 | 5 mg/ml | 1/12500 | 0.4 | |
| V5 | Anti-V53 | Monoclonal | Invitrogen | R960-25 | 1.07 mg/ml | 1/12500 | 0.0856 |
| Myc | Anti-Myc2 Polyclonal |
Polyclonal | Upstate | 06-549 | 1 mg/ml | 1/5000 | 0.2 |
| 9E103 | Monoclonal | Santa Cruz | Sc-40 | 0.2 mg/ml | 1/1000 | 0.2 | |
| HA | HA 113 | Monoclonal | Covance | MMS-101R | 2-3 mg/ml | 1/25000 | 0.1 |
| 12CA53 | Monoclonal | Roch Applied | 11 583 816 001 | 0.4 mg/ml | 1/5000 | 0.08 | |
| AU1 | Anti-AU13 | Monoclonal | Covance | MMS-130R | 5-7 mg/ml | 1/5000 | 1.2 |
| GFP | Anti-eGFP4 Polyclonal |
Polyclonal | In-house | - | - | 1/10000 | - |
1 affinity purified IgGs using a column bearing the inmmunizing peptide
2 affinity purified IgGs using a column bearing protein A
3 purification method not specified
4 not purified
In order to compare antibody dilutions, the optimal dilutions (based on current study) for IHC reckoned with the antibody concentration are mentioned in this table.